Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
06. Mai 2019 16:17 ET
|
Otonomy, Inc.
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
01. Mai 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
29. April 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
11. April 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Two Upcoming Investor Conferences
05. März 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
04. März 2019 16:18 ET
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06. November 2018 07:30 ET
|
Otonomy, Inc.
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company...
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
30. Oktober 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple...
Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
29. Oktober 2018 07:30 ET
|
Otonomy, Inc.
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the...
Otonomy to Report Second Quarter 2018 Financial Results and Provide Corporate Update
01. August 2018 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...